NEW YORK (GenomeWeb) – Agilent Technologies announced today that the US Food and Drug Administration has approved its Dako PD-L1 IHC 28-8 pharmDx complementary diagnostic for two additional indications: urothelial carcinoma (UC) and squamous cell carcinoma of the head and neck (SCCHN).
To read the full story....
Register for Free....and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.